UNIKUM Therapeutics ApS: Financial statements 2022
CVR: 41192925
Source: annual report 2022, Danish Business Authority
01/01/2022 – 31/12/2022
UNIKUM Therapeutics ApS (CVR 41192925) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK -3,315,358 and a net result of DKK -7,648,614 compared with DKK -5,555,369 the year before. Equity in the 2022 report amounted to DKK -15,293,981. The company had 7 employees in the financial year.
- Gross Profit
- DKK -3,315,358
- Profit/Loss
- DKK -7,648,614
- Equity
- DKK -15,293,981
- Total Assets
- DKK 3,057,295
- Employees
- 7
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2022 | - | -3.3M | -7.6M | -15.3M | 7 |
| 2021 | - | -2.7M | -5.6M | -7.6M | 5 |
| 2020 | - | -1.1M | -2.1M | -2.1M | 2 |
Official annual report
Keep an eye on UNIKUM Therapeutics ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
UNIKUM Therapeutics ApS has published its annual report for 2021. Gross profit came to DKK -2,726,200, and the net result was DKK -5,555,369.
About UNIKUM Therapeutics ApS
UNIKUM Therapeutics ApS is a Danish company of the type Anpartsselskab based in Risskov, founded in 2020. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Martin Roelsgaard Jakobsen. The board consists of Ulrik Bjerl Nielsen (chair), Martin Roelsgaard Jakobsen and Stefan Wildt. The company's owners include MEDIC ADVICE ApS, MR Jakobsen Holding ApS and BII Holdings A/S. The company has 2 employees (2025). In 2025, the company reported a gross profit of DKK -247,887 and a net result of DKK -859,076 compared with DKK -13,797,011 the year before. Equity in the 2025 report amounted to DKK -5,680,033.
